Filing summary
Important entity and period note: The supplied filing is GlycoMimetics, Inc.’s Form 10-K for the fiscal year ended December 31, 2018, filed March 6, 2019. It is not a filing for Crescent BioPharma, Inc.; the filing identifies the company as GlycoMimetics (Nasdaq: GLYC). It reports annual results, not a standalone 2018 fourth quarter.
Business context
GlycoMimetics was a clinical-stage biotechnology company developing glycomimetic drug candidates. Its lead programs were uproleselan for acute myeloid leukemia (AML), GMI-1359 for cancer, and rivipansel for sickle-cell vaso-occlusive crisis (VOC), which Pfizer licensed and was developing. The company had no approved products or meaningful recurring product revenue.
Financial performance and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $40.1 million | $24.1 million |
| General and administrative expense | $11.4 million | $9.8 million |
| Net loss | $48.3 million | $33.3 million |
| Net loss per share | $1.18 | $1.13 |
| Cash used in operating activities | $43.3 million | $29.8 million |
| Cash and cash equivalents at year-end | $209.9 million | $123.9 million |
| Total assets | $214.8 million | $128.6 million |
| Total liabilities | $9.4 million | $8.9 million |
Operating margin is not meaningful given the absence of revenue. The filing reports no debt balance. Cash and cash equivalents were the principal source of liquidity; total stockholders’ equity was $205.5 million at year-end 2018. Interest income was $3.2 million, up from $0.7 million, reflecting higher cash balances.
Material changes versus 2017
- Net loss increased by $15.0 million, while operating cash use rose by $13.6 million.
- R&D expense increased 66%, principally due to uproleselan manufacturing and clinical supply costs, including preparation for Phase 3 and collaborative trials.
- Cash increased by $86.0 million, largely because the March 2018 public offering generated $128.4 million in net proceeds. The offering issued 8.05 million shares.
- Weighted-average shares outstanding rose to 41.0 million from 29.4 million; the filing’s per-share loss narrowed slightly, from $1.13 to $1.18 (a larger loss per share).
Outlook, risks, and notable items
- Management expected existing cash to fund operations through top-line results from the uproleselan Phase 3 trial, anticipated by the end of 2020. This estimate depended on assumptions that could prove wrong; additional funding might be needed.
- The company-sponsored uproleselan Phase 3 trial in relapsed/refractory AML began enrollment in Q4 2018, targeted approximately 380 patients, and had expected top-line results by the end of 2020. The filing also describes planned NCI and HOVON trials and anticipated initiation of a GMI-1359 Phase 1b trial in 2019.
- Uproleselan Phase 1/2 results were compared with historical controls, not a concurrent control group. Phase 3 results remained uncertain; clinical failure, enrollment delays, safety findings, manufacturing issues, and regulatory review could delay or prevent approval.
- Pfizer’s rivipansel Phase 3 trial was expected to complete enrollment in early 2019, with top-line data anticipated in Q2 2019. Potential milestone and royalty payments were contingent on Pfizer’s development, regulatory, and commercial outcomes and were not assured.
- The company had an accumulated deficit of $200.6 million and expected continued losses. It relied on third-party manufacturers and clinical research organizations and had no established sales or marketing infrastructure.
- No material legal proceedings or off-balance-sheet arrangements were reported. The auditor issued an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting.
Most important facts for investors to verify
- Confirm the issuer: this is GlycoMimetics’ GLYC filing, not Crescent BioPharma’s.
- Check subsequent disclosures for actual uproleselan and rivipansel trial enrollment, results, and updated timelines.
- Assess cash runway against ongoing clinical and manufacturing costs, and the company’s need for further financing and potential dilution.
- Review the full filing and notes for share issuance, outstanding equity awards, lease commitments, and the conditions attached to Pfizer milestone and royalty payments.